A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study.

This phase II study in recurrent high-grade glioma evaluated the response rate, toxicities, and time to treatment failure of high-dose carboplatin modulated by a 24-h infusion of thymidine (75 g/m(2)). The trial was based on preclinical data and a prior phase I study ( J. Clin. Oncol. 17, 2922-2931,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Robins, H. Ian, Chang, Susan M., Prados, Michael D., Yung, W. K. Alfred, Hess, Kenneth, Schiff, David, Greenberg, Harry, Fink, Karen, Nicolas, Kelly, Kuhn, John G., Cloughesy, Timothy, Junck, Larry, Mehta, Minesh
Formato: Artigo
Lenguaje:Inglês
Publicado: 2002
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC1920656/
https://ncbi.nlm.nih.gov/pubmed/11916502
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares